^
Association details:
| Biomarker: | IFNG gene signature |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Excerpt:
Similarly, the ORR in urothelial cancer patients was approximately 3.5- or 7.5-fold higher in patients with IFNγ sig+ or PD-L1+ tumors, respectively, compared with those who were negative for these two biomarkers...
DOI:
10.1158/1078-0432.CCR-17-3451